Combining Sugemalimab with Chemotherapy for Advanced Lung Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II, open-label, single-arm study aims to assess the effectiveness and safety of using Sugemalimab in conjunction with chemotherapy for patients with unresectable stage III non-small cell lung cancer (NSCLC). The approach involves administering induction immunotherapy and chemotherapy, followed by treatment guided by a multidisciplinary team, which may include radiotherapy or surgery. The study focuses on patients whose disease is confirmed as unresectable but can still be treated with curative intent. The goal is to improve patient outcomes in this challenging cancer stage.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1.18 to 75 years old, both male and female;

2.ECOG score: 0-1;

3.Histopathologically or cytologically confirmed, stage III (AJCC 8th) non-small cell lung cancer;

4.Multidisciplinary team (MDT) discussion confirmed unresectable disease but can be treated by curative radiotherapy;

5.Measurable lesions available;

6.Major organ function is basically normal;

7.Estimated survival time is at least 6 months;

8.Non-surgically sterile female subjects of childbearing age must have a negative serum HCG test before inclusion.

Exclusion Criteria:

1. Histologically or cytologically confirmed mixed SCLC and NSCLC;
2. Subjects with driver gene mutations(EGFR mutation, ALK fusion, etc.);
3. Previous systemic anti-tumor therapy including immune checkpoint inhibitors for NSCLC;
4. Previous thoracic radiotherapy;
5. Subjects who participated in other clinical trials within 4 weeks or 5 drug half-lives(whichever is shorter) before the first dose;
6. Systemic immunostimulant therapy before the first dose;
7. Systemic immunosuppressive therapy before the first dose or were expected to require systemic immunosuppressive drugs during the study treatment;
8. Subjects with autoimmune diseases;
9. Other malignant tumors other than non-small cell lung cancer within 5 years before screening;
10. Known or suspected interstitial pneumonia;
11. Other moderate to severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity and seriously affect respiratory function;
12. Severe cardiovascular and cerebrovascular diseases;
13. Clinically significant bleeding symptoms or significant bleeding tendency within 1 month before the first dose;
14. Arteriovenous thrombotic events within 3 months before the first dose;
15. Positive HIV test;
16. Active hepatitis B or C;
17. Evidence of active tuberculosis infection within 1 year before the first dose;
18. Serious infection within 4 weeks before the first dose;
19. History of attenuated live vaccination 28 days before the first dose or expected to receive attenuated live vaccination during the study;
20. Major surgeries other than diagnosis or biopsy within 28 days prior to the first dose;
21. Previous or planned allogeneic bone marrow transplantation or solid organ transplantation;
22. History of severe allergic reactions to other monoclonal antibodies/fusion proteins;
23. Allergic to any component of the randomized treatment regimen;
24. Female subjects who are pregnant, lactating, or planning to get pregnant during the study period;
25. Subjects who have a known history of psychotropic drug abuse, alcoholism, or drug abuse;
26. Presence of other conditions that, in the opinion of the investigator, would make participation in this clinical trial inappropriate.

Where it's running

• Hunan Cancer Hospital
  Changsha, China Recruiting

Study contacts

• Principal investigator: Hui Wang, MD — the Department of Radiation Oncology
• Study coordinator: Huai Liu, MD
• Email: liuhuai@hnca.org.cn
• Phone: +8619918909231

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Intratumoral injection of N17350 in advanced solid tumors

  Aims to see if injected N17350 can shrink or control tumors in adults with advanced solid cancers who have few other options.

  Recruiting at 7 sites Phase 1/2 Onchilles Pharma Inc · Los Angeles, California and 8 other locations · NCT07339176

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

• PF-08634404 combined with other cancer medicines for advanced non-small cell lung cancer

  This will test whether PF-08634404 given with other cancer medicines is safe and can help adults with advanced or metastatic non-small cell lung cancer.

  Recruiting at 85 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 103 other locations · NCT07227298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.